IN2014DN09434A - - Google Patents

Download PDF

Info

Publication number
IN2014DN09434A
IN2014DN09434A IN9434DEN2014A IN2014DN09434A IN 2014DN09434 A IN2014DN09434 A IN 2014DN09434A IN 9434DEN2014 A IN9434DEN2014 A IN 9434DEN2014A IN 2014DN09434 A IN2014DN09434 A IN 2014DN09434A
Authority
IN
India
Prior art keywords
compounds
formula
salts
compositions
pharmaceutically acceptable
Prior art date
Application number
Inventor
Vincent P Sandanayaka
Sharon Shechter
Sharon Shacham
Dilara Mccauley
Erkan Baloglu
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09434(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of IN2014DN09434A publication Critical patent/IN2014DN09434A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
IN9434DEN2014 2012-05-09 2013-05-09 IN2014DN09434A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644802P 2012-05-09 2012-05-09
US201361798188P 2013-03-15 2013-03-15
PCT/US2013/040404 WO2013170068A2 (en) 2012-05-09 2013-05-09 Nuclear transport modulators and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN09434A true IN2014DN09434A (en) 2015-07-17

Family

ID=49448240

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9434DEN2014 IN2014DN09434A (en) 2012-05-09 2013-05-09

Country Status (32)

Country Link
US (10) US9096543B2 (en)
EP (3) EP3663291B1 (en)
JP (5) JP6195909B2 (en)
KR (5) KR20200115688A (en)
CN (1) CN104428295B (en)
AU (5) AU2013259384B2 (en)
BR (1) BR112014027860B8 (en)
CA (1) CA2872190C (en)
CL (1) CL2014003054A1 (en)
CO (1) CO7190242A2 (en)
CY (2) CY1120832T1 (en)
DK (2) DK2858991T3 (en)
EA (1) EA036639B1 (en)
ES (3) ES2794866T3 (en)
GE (1) GEP20237477B (en)
HR (2) HRP20181838T1 (en)
HU (2) HUE050452T2 (en)
IN (1) IN2014DN09434A (en)
LT (2) LT3404027T (en)
ME (1) ME03795B (en)
MX (1) MX364992B (en)
NZ (1) NZ702663A (en)
PE (1) PE20150128A1 (en)
PL (2) PL2858991T3 (en)
PT (2) PT2858991T (en)
RS (2) RS58058B1 (en)
SG (1) SG11201407268SA (en)
SI (2) SI3404027T1 (en)
SM (2) SMT202000347T1 (en)
UA (2) UA124922C2 (en)
WO (1) WO2013170068A2 (en)
ZA (1) ZA202004892B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002742B (en) 2010-03-05 2016-07-13 卡尔约药物治疗公司 Nuclear translocation regulator and application thereof
JP6106605B2 (en) 2011-01-17 2017-04-05 カリオファーム セラピューティクス，インコーポレイテッド Olefin-containing nuclear transport regulator and use thereof
JP6005740B2 (en) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド Hydrazide-containing nuclear transport regulators and uses thereof
KR102022715B1 (en) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 Nuclear transport modulators and uses thereof
NZ702663A (en) 2012-05-09 2017-03-31 Karyopharm Therapeutics Inc Nuclear transport modulators and uses thereof
TWI568722B (en) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 Triazolone compounds as mpges-1 inhibitors
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
HUE050215T2 (en) 2013-01-15 2020-11-30 Incyte Holdings Corp Thiazolecarboxamide and pyridinecarboxamide compounds are useful as Pim kinase inhibitors
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
TR201904455T4 (en) 2013-06-21 2019-04-22 Karyopharm Therapeutics Inc 1,2,4-triazoles and their uses as nuclear transport modulators.
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EA201690458A1 (en) 2013-08-23 2016-07-29 Инсайт Корпорейшн FURO- AND THYENOPYRIDINCARBOXAMIDES USED AS PIM-KINASE INHIBITORS
RU2663222C2 (en) * 2014-05-13 2018-08-02 КьюЭсЭй ГЛОБАЛ ИНК. Device and method of obtaining sources of gamma-radiation from enriched iridium
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
KR101734529B1 (en) 2015-05-08 2017-05-11 건국대학교 산학협력단 Method of screening compound for treating sepsis and pharmaceutical composition for treating sepsis
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
EP3341079A4 (en) * 2015-08-25 2019-05-08 President and Fellows of Harvard College METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US20190055283A1 (en) * 2016-02-29 2019-02-21 Ohio State Innovation Foundation Aza-peptide aldehydes and ketones
AU2017234678A1 (en) 2016-03-16 2018-08-16 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
EP3448234A4 (en) 2016-04-30 2019-05-01 Envision Diagnostics, Inc. MEDICAL DEVICES, SYSTEMS AND METHODS FOR OPERATING OCULAR EXAMINATIONS AND OCULOMETRY
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20230110828A (en) 2018-01-10 2023-07-25 엑스더블유파마 리미티드 Prodrugs of ketamine, compositions and uses thereof
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
WO2020092965A1 (en) 2018-11-01 2020-05-07 Karyopharm Therapeutics Inc. E2f1 as a biomarker for treatments using xpo1 inhibitors
MX2021006548A (en) 2018-12-06 2021-09-21 Biogen Ma Inc NEUROFILAMENT PROTEIN TO GUIDE THERAPEUTIC INTERVENTION IN AMYOTROPHIC LATERAL SCLEROSIS.
CN111606890A (en) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 Acryloyl group-containing nuclear transport modulators and uses thereof
CN109928939A (en) * 2019-02-27 2019-06-25 上海卡洛化学有限公司 A kind of preparation method of 2,2,6,6- tetramethyl morpholine
BR112021021706A2 (en) * 2019-05-01 2022-04-19 Karyopharm Therapeutics Inc Process for preparing xpo1 inhibitors and intermediates for use in preparing xp01 inhibitors
CN111145135B (en) * 2019-12-30 2021-08-10 腾讯科技（深圳）有限公司 Image descrambling processing method, device, equipment and storage medium
JP7658052B2 (en) 2021-04-01 2025-04-08 アルプスアルパイン株式会社 Operation detection device
EP4559522A3 (en) 2021-08-13 2025-07-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
TWI857509B (en) * 2022-03-07 2024-10-01 高雄醫學大學 Methods for treating hepatitis b virus infection

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017398A (en) 1911-01-16 1912-02-13 John E Folsom Telegraph-key.
KR840000529A (en) 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 Method for preparing indole derivative
CS229934B2 (en) 1981-07-07 1984-07-16 Pfizer Production method subst.indolylacryte acid derivative
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (en) 1990-02-23 2000-11-20 武田薬品工業株式会社 Condensed thiazole compound
IL97249A (en) 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd 4,5,6,7- Tetrahydrothiazolo (5,4-b) pyridine and 5,6-dihydro-4h pyrrolo (3,2-d) thiazolo compounds, their production and pharmaceutical compositions containing them
US5541213A (en) 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (en) 1994-11-23 2002-07-24 纽罗根公司 Certain 4 -aminomethyl -2 -substituted imidazole derivatives and 2 -aminomethyl -4 -substituted imidazole derivatives, new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (en) 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-membered heterocycles, pharmaceutical agents containing said compounds and the use thereof and methods of producing them
US6214818B1 (en) 1996-04-04 2001-04-10 Shionogi & Co., Ltd. Cephem compounds and pharmaceutical compositions containing the same
JP4054992B2 (en) 1996-04-25 2008-03-05 日産化学工業株式会社 Ethylene derivatives and pest control agents
DE69723267T2 (en) 1996-04-25 2004-04-22 Nissan Chemical Industries, Ltd. ETHYLENE DERIVATIVES AND PESTICIDES
DE19624659A1 (en) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkene and pyridylalkanoic acid amides
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (en) 1997-12-19 2010-02-17 武田薬品工業株式会社 Anilide derivatives, their production and use
WO1999050264A1 (en) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
AR029803A1 (en) 2000-02-21 2003-07-16 Smithkline Beecham Plc IMIDAZOLS REPLACED WITH PIRIDILE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
DE60115279T2 (en) 2000-09-29 2006-12-28 Topotarget Uk Ltd., Abingdon CARBOXIC ACID DERIVATIVES CONTAIN AN AMID GROUP AS HDAC INHIBITORS
JP3608050B2 (en) 2001-07-24 2005-01-05 トヨタ自動車株式会社 Rollover discrimination device
KR20100107509A (en) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 Inhibitors of histone deacetylase
AU2003287965A1 (en) 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (en) 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New amide compounds having MCH antagonist activity and medicaments containing these compounds
JP4145230B2 (en) 2002-11-01 2008-09-03 武田薬品工業株式会社 Preventive and therapeutic agents for neurological disorders
KR20050062645A (en) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 Agent for preventing or treating neuropathy
ATE552253T1 (en) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-SUBSTITUTED-6-ARYL-PYRIDINE DERIVATIVES AS LIGANDS FOR C5A RECEPTORS
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
CN101014595A (en) 2004-08-11 2007-08-08 杏林制药株式会社 Novel cyclic aminobenzoic acid derivative
WO2006019020A1 (en) 2004-08-16 2006-02-23 Sankyo Company, Limited Substituted ureas
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
WO2007058338A2 (en) 2005-11-15 2007-05-24 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP2007210929A (en) 2006-02-09 2007-08-23 Sankyo Co Ltd Medicine containing urea compound
CA2643796A1 (en) 2006-03-09 2007-09-13 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivatives
WO2007118137A1 (en) 2006-04-07 2007-10-18 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
US8404726B2 (en) 2006-04-18 2013-03-26 Nippon Chemiphar Co. Ltd. Activating agent for peroxisome proliferator activated receptor δ
JP4999923B2 (en) 2006-06-13 2012-08-15 中国科学院上海薬物研究所 Heterocyclic non-nucleoside compounds, antiviral pharmaceutical compositions, and drugs for treating viral diseases
CN100503571C (en) 2006-07-12 2009-06-24 中国药科大学 Tetrahydroisoquinoline derivatives, preparation method and medical use thereof
EP2054411B1 (en) 2006-07-27 2014-08-20 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
ES2376668T3 (en) 2006-09-05 2012-03-15 Kyowa Hakko Kirin Co., Ltd. IMIDAZOL DERIVATIVE
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
EP2003118A1 (en) 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Cinnamic acid derivatives as modulators of EP2 receptors
JP2010531841A (en) * 2007-07-04 2010-09-30 ノイロサーチ アクティーゼルスカブ Novel pyrazole derivatives useful as potassium channel modulators
WO2011006100A1 (en) 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Method of wound healing and scar modulation
WO2011069039A1 (en) * 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hydrazone and diacyl hydrazine compounds and methods of use
CN103002742B (en) * 2010-03-05 2016-07-13 卡尔约药物治疗公司 Nuclear translocation regulator and application thereof
JP6106605B2 (en) * 2011-01-17 2017-04-05 カリオファーム セラピューティクス，インコーポレイテッド Olefin-containing nuclear transport regulator and use thereof
KR102022715B1 (en) 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 Nuclear transport modulators and uses thereof
JP6005740B2 (en) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド Hydrazide-containing nuclear transport regulators and uses thereof
WO2013020024A2 (en) 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
NZ702663A (en) * 2012-05-09 2017-03-31 Karyopharm Therapeutics Inc Nuclear transport modulators and uses thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
TR201904455T4 (en) 2013-06-21 2019-04-22 Karyopharm Therapeutics Inc 1,2,4-triazoles and their uses as nuclear transport modulators.
US11567063B2 (en) 2013-11-15 2023-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for assessing cell viability or predicting cell response to a treatment using cell movement
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
US10993943B2 (en) 2017-01-05 2021-05-04 Watson Laboratories Inc. Crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
AU2013259384A1 (en) 2014-12-18
ES2794866T3 (en) 2020-11-19
ES2702279T3 (en) 2019-02-28
CA2872190A1 (en) 2013-11-14
EP3663291B1 (en) 2024-12-18
HK1209420A1 (en) 2016-04-01
EP3404027A1 (en) 2018-11-21
JP2018012715A (en) 2018-01-25
GEP20237477B (en) 2023-03-27
HUE050452T2 (en) 2021-03-29
US20160145246A1 (en) 2016-05-26
US20190008833A1 (en) 2019-01-10
US20150111893A1 (en) 2015-04-23
JP2015516434A (en) 2015-06-11
SI3404027T1 (en) 2020-08-31
KR20150018809A (en) 2015-02-24
BR112014027860B1 (en) 2022-03-08
SMT202000347T1 (en) 2020-07-08
LT2858991T (en) 2018-11-26
JP2018172444A (en) 2018-11-08
AU2021221398A1 (en) 2021-09-16
US9861614B2 (en) 2018-01-09
ME03795B (en) 2021-04-20
JP2021063104A (en) 2021-04-22
US9266843B2 (en) 2016-02-23
SI2858991T1 (en) 2018-12-31
RS60424B1 (en) 2020-07-31
AU2016222459A1 (en) 2016-09-22
PT2858991T (en) 2018-12-17
DK3404027T3 (en) 2020-06-02
KR20200115688A (en) 2020-10-07
US20180289675A1 (en) 2018-10-11
AU2021221398B2 (en) 2023-08-17
US10722497B2 (en) 2020-07-28
US20160354347A1 (en) 2016-12-08
BR112014027860A2 (en) 2017-06-27
WO2013170068A3 (en) 2014-02-20
PL3404027T3 (en) 2020-09-21
EP3663291A1 (en) 2020-06-10
KR102095429B1 (en) 2020-03-31
AU2019272017A1 (en) 2019-12-19
US9096543B2 (en) 2015-08-04
NZ702663A (en) 2017-03-31
US20130317031A1 (en) 2013-11-28
ES3016982T3 (en) 2025-05-12
US11318120B2 (en) 2022-05-03
US10058535B2 (en) 2018-08-28
CA2872190C (en) 2024-06-25
JP6195909B2 (en) 2017-09-13
CN104428295B (en) 2017-08-08
AU2019272017B2 (en) 2021-05-27
US20200038373A1 (en) 2020-02-06
US9585874B2 (en) 2017-03-07
UA118085C2 (en) 2018-11-26
HUE040427T2 (en) 2019-03-28
PL2858991T3 (en) 2019-01-31
WO2013170068A2 (en) 2013-11-14
KR20200041986A (en) 2020-04-22
KR20200118240A (en) 2020-10-14
AU2018201012A1 (en) 2018-03-01
SG11201407268SA (en) 2015-01-29
US20210251968A1 (en) 2021-08-19
UA124922C2 (en) 2021-12-15
EP2858991B1 (en) 2018-08-08
EA201492050A1 (en) 2015-07-30
CO7190242A2 (en) 2015-02-19
US20200230110A1 (en) 2020-07-23
US20170319551A1 (en) 2017-11-09
SMT201800686T1 (en) 2019-01-11
ZA202004892B (en) 2023-03-29
AU2013259384B2 (en) 2016-06-02
JP2020037585A (en) 2020-03-12
EA036639B1 (en) 2020-12-02
CY1123476T1 (en) 2022-03-24
HRP20200876T1 (en) 2020-09-04
EP2858991A2 (en) 2015-04-15
PT3404027T (en) 2020-03-30
US10925859B2 (en) 2021-02-23
US10617677B2 (en) 2020-04-14
CN104428295A (en) 2015-03-18
CY1120832T1 (en) 2019-12-11
JP6818849B2 (en) 2021-01-20
MX364992B (en) 2019-05-17
KR102163377B1 (en) 2020-10-08
KR102165177B1 (en) 2020-10-13
BR112014027860B8 (en) 2024-04-30
KR20200041984A (en) 2020-04-22
AU2018201012B2 (en) 2019-12-05
US10335393B2 (en) 2019-07-02
EP3404027B1 (en) 2020-03-04
MX2014013551A (en) 2015-01-16
CL2014003054A1 (en) 2015-05-15
KR102223028B1 (en) 2021-03-03
DK2858991T3 (en) 2018-11-26
PE20150128A1 (en) 2015-02-23
LT3404027T (en) 2020-07-10
HRP20181838T1 (en) 2018-12-28
RS58058B1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
IN2014DN09434A (en)
MX2015016983A (en) Nuclear transport modulators and uses thereof.
IN2015DN01156A (en)
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX345928B (en) Therapeutically active compositions and their methods of use.
TN2014000356A1 (en) Heterocyclyl compounds as mek inhibitors
EA201391615A1 (en) DATED POTENTIATORS CFTR
IN2015DN01119A (en)
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
PH12015500746A1 (en) Benzamides
MX2015004362A (en) Ketamine derivatives.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
IN2014DN09347A (en)
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MX369774B (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders.
WO2013038200A3 (en) Neurodevelopmental disorders
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2014001862A (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.